

FORUM ON
IMMUNOPATHOLOGICAL
DISEASES AND THERAPEUTICS

CONTENTS VOLUME 7, 2016

Page Range of Issues; Issues 1-2: 1–158; Issues 3-4: 159–264

ISSUES 1-2

PROBIOTICS AND IMMUNITY
GUEST EDITOR: BENJAMIN BONAVIDA

- Probiotics and the Innate and Adaptive Immune Responses in Premature Infants** 1
M.A. Underwood
- Probiotics in Human Health** 17
A.K. Goyal, T. Garg, & G. Rath
- Gut Microbiota: Potential Impact on Chemotherapy-Related Adverse and Therapeutic Effects** 33
Y. Touchefeu, M. Salimon, & E. Montassier
- Activation of Natural Killer Cells by Probiotics** 41
N. Aziz & B. Bonavida

CONTRASTING ROLES OF KLF4 AS AN ONCOGENE OR TUMOR SUPPRESSOR
GUEST EDITORS: BENJAMIN BONAVIDA & MARIO VEGA

- Role of Immune-Cell-Expressing Kruppel-Like Factor 4 in Cancer Development** 61
W. Ai
- Identification of the Alternating Oncogenic and Tumor-Suppressor Activities of Kruppel-Like Factor 4 in Various Human Cancers** 77
E. Moyal, S. Kaufhold, & B. Bonavida
- Dual Roles of Kruppel-Like Factor 4 as a Tumor Suppressor or Oncogene** 95
W-T. Yang & P-S. Zheng
- Regulation of the Cancer Stem Cell Phenotype by Raf Kinase Inhibitor Protein via Its Association with Kruppel-Like Factor 4** 107
S. Wottrich & B. Bonavida
- KLF4 in Ovarian Cancer** 119
J. Yue, B. Wang, Z. Du, & L.M. Pfeffer
- The Transcription Regulator Kruppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma** 131
S.K. Ray
- Bifunctional Role of Kruppel-Like Factor 4 in Hematological Malignancies** 141
M. Morales-Martinez, L.A. Franco-Cea, L. Moreno Vargas, O. Martinez-Maza, S. Huerta-Yeppez, & M.I. Vega
- Kruppel-Like Factor 4: From Physiological Functions to Tumor Therapy** 153
R. Zhao, Y. Lai, & P. Li

ISSUES 3-4

JAMES N MILLER: A JOURNEY FIGHTING INFECTIOUS DISEASES

GUEST EDITOR: BENJAMIN BONAVIDA

| | |
|---|------------|
| PREFACE: James N. Miller: A Journey Fighting Infectious Diseases | v |
| <i>B. Bonavida</i> | |
| Dr. James N. Miller: Virtuoso of All Spirochetes | 159 |
| <i>J. Nally</i> | |
| The University of California at Los Angeles and James Miller: A Powerhouse | 161 |
| <i>N.W. Charon</i> | |
| A Tribute to James N. Miller | 163 |
| <i>L.K. Bockenstedt</i> | |
| A Tribute to James N. Miller: Colleague—Friend—Mentor | 165 |
| <i>B. Bonavida</i> | |
| The Miller Hypothesis | 167 |
| <i>D.A. Haake</i> | |
| A Journey Through Time: The Foundational Studies of Dr. James N. Miller and Their Influence on Current-Day Syphilis Research | 175 |
| <i>C.E. Cameron</i> | |
| Why Are There Two Genetically Distinct Syphilis-Causing Strains? | 181 |
| <i>D. Šmajš, L. Mikalová, M. Strouhal, & L. Grillová</i> | |
| Role of the VlsE Lipoprotein in Immune Avoidance by the Lyme Disease Spirochete <i>Borrelia burgdorferi</i> | 191 |
| <i>T. Bankhead</i> | |
| Gene Regulation During the Enzootic Cycle of the Lyme Disease Spirochete | 205 |
| <i>D.S. Samuels & L.R.N. Samuels</i> | |
| Immune Complex Analysis in Active Lyme Disease | 213 |
| <i>S.E. Schutzer, & P.K. Coyle</i> | |
| Immunopathology of Experimental Models of Syphilis, Influenza, and Asthma | 225 |
| <i>S. Sell</i> | |
| <i>Chlamydia pneumoniae</i> Infection and Inflammatory Diseases | 237 |
| <i>R.A. Porritt & T.R. Crother</i> | |
| Gonorrhea: Immune Escape and Immunotherapeutic Strategies | 255 |
| <i>A.H. Lao & B. Bonavida</i> | |

FORUM ON
IMMUNOPATHOLOGICAL
DISEASES AND THERAPEUTICS

AUTHOR INDEX, VOLUME 7, 2016

Page Range of Issues; Issues 1-2: 1–158; Issues 3-4: 159–264

| | |
|-------------------------------------|------------------------|
| Ai, W., 61 | Moreno Vargas, L., 141 |
| Aziz, N., 41 | Moyal, E., 77 |
| Bankhead, T., 191 | Nally, J., 159 |
| Bockenstedt, L.K., 163 | Pfeffer, L.M., 119 |
| Bonavida, B., 41, 77, 107, 165, 255 | Porritt, R.A., 237 |
| Cameron, C.E., 175 | Rath, G., 17 |
| Charon, N.W., 161 | Ray, S.K., 131 |
| Coyle, P.K., 213 | Salimon, M., 33 |
| Crother, T.R., 237 | Samuels, D.S., 205 |
| Du, Z., 119 | Samuels, L.R.N., 205 |
| Franco-Cea, L.A., 141 | Schutzer, S.E., 213 |
| Garg, T., 17 | Sell, S., 225 |
| Goyal, A.K., 17 | Šmajš, D., 181 |
| Grillová, L., 181 | Strouhal, M., 181 |
| Haake, D.A., 167 | Touchefeu, Y., 33 |
| Huerta-Yepez, S., 141 | Underwood, M.A., 1 |
| Kaufhold, S., 77 | Vega, M.I., 141 |
| Lai, Y., 153 | Wang, B., 119 |
| Lao, A.H., 255 | Wottrich, S., 107 |
| Li, P., 153 | Yang, W-T., 95 |
| Martinez-Maza, O., 141 | Yue, J., 119 |
| Mikalová, L., 181 | Zhao, R., 153 |
| Montassier, E., 33 | Zheng, P-S., 95 |
| Morales-Martinez, M., 141 | |

FORUM ON
IMMUNOPATHOLOGICAL
DISEASES AND THERAPEUTICS

SUBJECT INDEX, VOLUME 7, 2016

Page Range of Issues; Issues 1-2: 1–158; Issues 3-4: 159–264

- alternative sigma factor RpoS, 205
Alzheimer's, 237
antigenic variation, 191
arthritis, 237
asthma, 225, 237
atherosclerosis, 237
bifidobacteria, 1
Borrelia, 191, 213
Burkitt lymphoma, 141
cancer stem cell (CSC), 61, 107
cancer, 17, 77, 237
cell signaling, 107
chemotherapy, 33
Chlamydia pneumoniae, 237
delayed-type hypersensitivity, 225
dietary supplements, 17
epithelial-to-mesenchymal transition (EMT),
107, 119
fibroblast-specific protein 1(FSP1), 61
fibrocytes, 61
glioblastoma, 127
gut microbiota, 33
gut-associated lymphoid tissue (GALT), 41
hematological malignancies, 141
immune complexes, 213
immune complex vasculitis, 225
immune evasion, 191
immune suppression, 255
immunity, 41
immunopathology, 225
immunoprotection, 167
immunosurveillance, 61
infection, 41
infectious disease, 17
influenza, 225
James Miller, 175
Kruppel-like factor 4 (KLF4), 61, 77, 95, 107,
119, 127, 141, 153
lactobacilli, 1
Leptospira interrogans, 167
leukemia, 153
Lyme disease, 191, 213
microbial evolution, 181
mucositis, 33
myeloid-derived suppressor cells (MDSCs), 61
natural killer, 41
necrotizing enterocolitis, 1
Neisseria gonorrhoeae, 255
neuroblastoma, 127
oncogene, 77, 95, 127
ovarian cancer, 119
probiotics, 1, 17, 33, 41
Raf kinase inhibitor protein (RKIP), 107
resistance, 255
second messenger, 205
sepsis, 1
solid tumor, 153
stringent response, 205
surface immunoprecipitation, 167
surface protein, 167
surfaceome, 167
syphilis, 175, 181, 225
T-cell cytotoxicity, 225
therapeutic strategies, 255
transposon sequencing, 167
Treponema pallidum, 167, 175
Treponema pallidum subsp. pallidum, 181
tumor suppressor, 77, 95, 127
vaccines, 17, 255
variable major protein-like sequence E
lipoprotein.(VlsE), 191
Ying Yang 1 (YY1), 141